Designing Longevity
Skip to main content
Strong EvidencePeptide

PT-141 (Bremelanotide)

Vyleesi

Melanocortin Receptor Agonist

Last updated: August 2026
Share:

Evidence Level: Strong Evidence

Multiple large human trials, FDA approval, established safety profile

Regulatory Status: FDA-approved June 21, 2019 as Vyleesi, for acquired generalized hypoactive sexual desire disorder in premenopausal women. Use in men is off-label.

PT-141, sold as Vyleesi, is an on-demand injection that acts on the brain rather than on blood flow. It activates involved in sexual desire. The FDA approved it in 2019 for premenopausal women with low sexual desire. Its trials were positive and its was small, and both of those things are true at once.

How It Works

Almost every drug in this space works on plumbing. Viagra and Cialis relax blood vessels so more blood reaches the genitals. They help with the mechanics of arousal. They do nothing for wanting sex in the first place.

PT-141 works somewhere else entirely.

in the brain. PT-141 activates , primarily MC4R, in the central nervous system. These receptors sit in circuits involved in appetite, arousal, and motivation. Activating them appears to increase sexual desire itself rather than the physical response to it.

Its origin is a good story. PT-141 came out of research on melanotan II, a synthetic peptide developed for tanning. Trial participants kept reporting unexpected erections and increased arousal. Researchers isolated the fragment responsible for the sexual effect from the one responsible for pigmentation, and that fragment became bremelanotide.

On-demand, not daily. You use it 45 minutes or more before anticipated sexual activity, not every day. That is unusual in this category and, for many people, more acceptable than a daily pill.

Now the uncomfortable part. The RECONNECT trials met their endpoints with statistical significance, which is why the drug is approved. But the were small: Cohen's d of 0.39 for improving desire and 0.27 for reducing distress. In plain terms, the average woman on bremelanotide did better than the average woman on placebo, but the distributions overlap heavily. A lot of people will not notice a difference.

That is not a reason to dismiss the drug. Low sexual desire is genuinely distressing and the treatment options are thin. It is a reason to go in with calibrated expectations rather than the ones the marketing sets.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Libido / sexual functionHigh certainty

Increases sexual desire and reduces related distress in premenopausal women with hypoactive sexual desire disorder, with a small effect size.

Population: Premenopausal women with acquired, generalized hypoactive sexual desire disorder

Why this rating

Two large, identically designed, randomized, double-blind, placebo-controlled phase 3 trials both met their co-primary endpoints, and the results supported FDA approval. The certainty that the effect is real is high. Note that high certainty is a statement about confidence in the estimate, not about the size of the benefit: the effect sizes here (Cohen's d 0.39 and 0.27) are small, and we are confident they are small.

Supporting studies

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade
Libido / sexual functionLow certainty

Improves erectile function or sexual desire in men.

Population: Adult men. Not an approved population.

Why this rating

Bremelanotide was studied in men in earlier development, including intranasal formulations, before the program was redirected to women. Those earlier studies showed activity but the male program did not proceed to approval, and the published evidence base for men is far smaller and less accessible than the RECONNECT trials. Off-label use in men is common and is not supported by anything comparable to the female evidence.

GRADE downgrade factors applied

  • Indirectness: Studied population, intervention, comparator, or outcome differs from the question being answered.
  • Publication bias: Suspicion that negative or null results were not published, inflating apparent effect.

Supporting studies

  • Bremelanotide clinical development programRandomized Controlled Trial
    2019

    FDA approval was granted only for acquired, generalized hypoactive sexual desire disorder in premenopausal women. No male indication was approved.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

  • FDA-approved, with real manufacturing standards, a labeled dose, and known safety data
  • Works on desire itself rather than on blood flow, which is a different and largely unaddressed problem
  • Used on demand rather than daily, so exposure is limited to when you actually want it
  • Two large identically designed phase 3 trials both met their
  • Works in women, a population that erectile dysfunction drugs do nothing for
  • Effective regardless of whether the underlying cause is physical or psychological, since it acts centrally

Risks & Considerations

  • The is modest. Cohen's d was 0.39 for desire and 0.27 for distress, meaning many users will not notice much
  • Nausea is common and can be significant, affecting roughly 40% of trial participants
  • Can cause transient increases in blood pressure and decreases in heart rate, so it is not for people with uncontrolled hypertension or known cardiovascular disease
  • Can cause darkening of the skin, gums, or face, which may not fully reverse, particularly with frequent use
  • Approved only for premenopausal women. Use in men or postmenopausal women is off-label with much thinner evidence
  • Labeled for no more than one dose in 24 hours and no more than eight doses per month
  • Headache and flushing are frequent

Dosing Information

PT-141 has an approved label with clear limits, which is worth following even if you obtain it another way.

  • •Approved dose: 1.75mg subcutaneously, as needed, using an autoinjector in the thigh or abdomen
  • •Take at least 45 minutes before anticipated sexual activity
  • •Maximum of one dose in any 24-hour period
  • •Maximum of eight doses per month, a limit set partly because of the skin pigmentation risk
  • •Anti-nausea medication is sometimes used alongside it, given how common nausea is
  • •Gray-market vendors sell it in vials at varying doses, which is not the approved presentation

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

  • 1Set expectations honestly. This is a modest effect in trials, not a switch
  • 2Take it on a relatively empty stomach and consider having an anti-nausea option available for the first few uses
  • 3Respect the eight-doses-per-month limit. The pigmentation risk rises with cumulative exposure
  • 4If you have high blood pressure or heart disease, discuss this with your doctor first. The blood pressure effect is real
  • 5If desire is the problem, this targets the right thing. If arousal or erection is the problem, a PDE5 inhibitor is the better-matched tool
  • 6The approved product is Vyleesi. Anything else is unregulated material at an unverified dose

Key Research

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT)

Obstetrics and Gynecology, 2019

Both identically designed trials met their co-primary endpoints. Treatment differences versus placebo were 0.35 on the desire scale and 0.33 on the distress item. Effect sizes were 0.39 for desire and 0.27 for distress.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All TreatmentsFind Your Goal

Always consult a healthcare provider before starting any treatment.

Frequently Asked Questions

What is PT-141 and how is it different from Viagra?

PT-141, sold as Vyleesi, works in the brain rather than on blood vessels. It activates involved in sexual desire. Viagra and similar drugs are PDE5 inhibitors that increase blood flow, which helps with the physical mechanics of arousal but does nothing for whether you want sex. They address different problems and are not interchangeable.

Does PT-141 actually work?

Yes, in the statistical sense, and modestly. Two large phase 3 trials met their , which is why the FDA approved it. But the were small: Cohen's d of 0.39 for desire and 0.27 for distress. That means a real average benefit with heavy overlap between the treated and placebo groups. Some people notice a clear difference and many do not.

Is PT-141 FDA-approved?

Yes. The FDA approved bremelanotide as Vyleesi on June 21, 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That is the only approved indication. Use in men, in postmenopausal women, or for general libido enhancement is off-label.

Can men use PT-141?

Men do use it off-label, and bremelanotide was studied in men earlier in its development before the program shifted focus. But no male indication was ever approved, and the published evidence in men is far thinner than the two large trials that supported the female approval. If you are a man considering it, understand that you are on much weaker evidentiary ground.

What are the side effects of PT-141?

Nausea is the big one, affecting roughly 40% of trial participants, and it can be significant. Flushing and headache are also common. It causes transient increases in blood pressure and decreases in heart rate, so it is not appropriate for people with uncontrolled hypertension or known cardiovascular disease. It can also cause darkening of the skin, gums, or face, which may not fully reverse with repeated use.

Why is PT-141 limited to eight doses a month?

Primarily because of the pigmentation risk. PT-141 descends from research on melanotan II, a tanning peptide, and it retains some activity at the receptors that drive melanin production. Skin, gum, and facial darkening becomes more likely with cumulative exposure, and it does not always reverse. The label caps use at one dose per day and eight per month for that reason.

How long does PT-141 take to work and how long does it last?

The label directs you to take it at least 45 minutes before anticipated sexual activity. Reported effects last for several hours, though this varies considerably between people. It is designed as an on-demand treatment rather than something you take daily.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Hormone Balance Guide

Related Peptides

SermorelinGrowth Hormone-Releasing Hormone Analog

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated August 2026.

Found this helpful? Share it or save it for later.

Share: